Before a NovaStem consultation: cell-therapy terms, authorization, and safety

Short answer

The program name NovaStem does not identify the cell type, processing method, regulatory status, or expected outcome. Ask for the exact composition, autologous or allogeneic source, administration method, evidence, alternatives, and applicable authorization.

What to check

Identify the exact material

Ask for the precise name of the cells, tissue, or components; whether they are autologous or allogeneic; and how collection, processing, storage, and administration are handled.

Authorization is product-specific

The broad term stem cell is not an approval category. Verify the country, product, indication, treatment area, and method against an official document.

Scope of U.S. sources

FDA materials describe U.S. regulation and do not determine Korean authorization. They do show why FDA approval should never be inferred from a clinic program name alone.

Safety and limitations

• Autologous sourcing does not eliminate infection, bleeding, pain, collection risk, processing risk, or unexpected reactions.
• Skin regeneration, rejuvenation, disease treatment, and a fixed duration of benefit cannot be promised to every patient.
• Disclose medical conditions, medication, pregnancy or breastfeeding, infection, and immune-related history before treatment.

This article provides general information and does not replace an individual diagnosis or prescription. Regulatory status and suitability vary by country, product, treatment area, and patient.

Sources

• U.S. FDA: Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes
• U.S. FDA: Approved Cellular and Gene Therapy Products
• ISSCR: Patient guide to cell-based interventions

Related Cellinique information

• NovaStem treatment overview
• Treatment safety guide
• Contact and consultation

Frequently asked questions

Q1. Is NovaStem an FDA-approved treatment using pure stem cells?

That cannot be established from the program name. FDA authorization is product- and indication-specific, and U.S. status does not determine Korean authorization. Ask for the exact material and the applicable Korean documentation.

Q2. Does autologous mean there is no rejection or side effect?

No. Some immune considerations may differ, but collection, processing, and administration can still involve infection, bleeding, pain, and other unexpected reactions.